NDAORALTABLETPriority Review
Approved
Apr 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
LODOSYN (carbidopa tablets) by Atonco is dopa decarboxylase inhibitors [moa]. Approved for aromatic amino acid decarboxylation inhibitor [epc]. First approved in 1977.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LODOSYN (carbidopa) is an oral tablet that functions as a DOPA decarboxylase inhibitor, blocking the conversion of levodopa to dopamine in the periphery. It is used as an adjunct therapy in Parkinson's disease to enhance levodopa bioavailability and reduce peripheral side effects. The drug works by preventing premature dopamine synthesis outside the central nervous system, allowing more levodopa to reach the brain.
LOE Approaching
With LOE approaching and minimal linked job activity, the brand team is likely small and focused on defensive positioning rather than growth initiatives.
Mechanism of Action
DOPA Decarboxylase Inhibitors
Pharmacologic Class:
Aromatic Amino Acid Decarboxylation Inhibitor
Indications (1)
Career Relevance
LODOSYN presents minimal career growth opportunity with zero currently linked job openings and an LOE-approaching lifecycle. Roles on this product are likely consolidating or transitioning to other Parkinson's therapies, making it a suboptimal choice for professionals seeking career expansion or long-term product stability.
Worked on LODOSYN at Atonco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.